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Natural Gene Therapy May Occur in All Patients with
Generalized Non-Herlitz Junctional Epidermolysis
Bullosa with COL17A1 Mutations
Anna M.G. Pasmooij1, Miranda Nijenhuis1, Renske Brander1 and Marcel F. Jonkman1
Mutations in the type XVII collagen gene (COL17A1) result in the blistering disorder non-Herlitz junctional
epidermolysis bullosa (JEB-nH). The incidence of revertant mosaicism, also called ‘‘natural gene therapy’’, was
identified in a cohort of 14 patients with JEB-nH caused by COL17A1 mutations in the Netherlands. Five different
in vivo reversions, all correcting the germ-line COL17A1 mutation c.2237delG in exon 30, were found in four
mosaic JEB-nH patients. The correcting DNA changes involved a wide variety of somatic mutations, from which
an indel mutation (c.2228-101_2263þ 70delins15) and a large deletion of 2,165 base pairs (c.2227þ 153_2336-
318del) have not been previously observed in patients with revertant mosaicism. Our results show that there is
no preference for a repair mechanism. Moreover, revertant mosaicism was confirmed on a DNA level in 6 out of
10 generalized JEB-nH patients. Further, photo-material and clinical history of the other four generalized JEB-nH
patients demonstrated that each patient has revertant skin patches. In contrast, revertant mosaicism was not
detected in the four localized JEB-nH patients. The fact that so many, if not all, generalized JEB-nH COL17A1
patients have revertant patches offers opportunities for cell therapies in which the patient’s own naturally
corrected cells are used as a source.
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INTRODUCTION
Revertant mosaicism refers to the coexistence of cells
carrying inherited genetic mutations with cells in which the
inherited disease-causing mutation is corrected by a sponta-
neous genetic event, thereby giving rise to a clinically healthy
phenotype. This phenomenon has been reported in several
genetic disorders, affecting self-regenerating organ systems,
such as skin, blood, and liver (for review see Jonkman, 1999;
Hirschhorn, 2003; Lai-Cheong et al., 2011a). Several genetic
mechanisms can underlie this natural gene therapy, including
true back mutation, intragenic crossover, mitotic gene
conversion, and second-site mutation (Kvittingen et al.,
1994; Ellis et al., 1995; Jonkman et al., 1997).
In skin, in vivo reversion has been described for the
genetic blistering disorder epidermolysis bullosa (EB), which
is characterized by skin fragility that is accompanied by
blister formation. Mutations in as many as 15 different EB
genes can result in this group of genetic skin disorders. Of
these 15 genes, five have shown to be reverted, i.e., KRT14
encoding keratin 14 (Schuilenga-Hut et al., 2002; Smith
et al., 2004), LAMB3 encoding the b3 chain of laminin-332
(Pasmooij et al., 2007a), COL17A1 encoding type XVII
collagen (Col17, Jonkman et al., 1997; Darling et al., 1999;
Pasmooij et al., 2005), COL7A1 encoding type VII collagen
(Almaani et al., 2010; Pasmooij et al., 2010; Van den Akker
et al., 2011), and FERMT1 encoding kindlin-1 (Lai-Cheong
et al., 2011b).
Initially, revertant mosaicism was thought to be a rare
phenomenon. Recently, however, we showed that 35% of
the patients with non-Herlitz junctional EB (JEB-nH), due to
mutations in COL17A1 or LAMB3, carry revertant patches,
indicating that revertant mosaicism is more common than
was previously anticipated (Jonkman and Pasmooij, 2009).
These clinically healthy skin areas manifested as patches
of homogeneously pigmented skin in the patients with
COL17A1 mutations. Another amazing example of the
frequency of these in vivo reversions is the presence of
hundreds or thousands of pale confetti-like revertant spots
that appear across the body surface in the patients with
ichthyosis with confetti, because of dominant KRT10 muta-
tions that change the reading frame and produce an arginine-
rich C-terminal peptide (Choate et al., 2010). Each reversion
was because of mitotic recombination. Unlike these patients,
we report here on four patients with COL17A1 mutations in
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which the inherited c.2237delG mutation was corrected in
five different ways, showing that there is no preference for
a certain correction mechanism. Moreover, we investigated
the incidence of natural gene therapy in JEB-nH patients in
the Netherlands, indicating that the majority, if not all, of the
JEB-nH patients carry one or more revertant patches.
RESULTS
Four patients with type XVII collagen–deficient generalized
JEB-nH were studied. Patients EB035-01 and EB035-02 were
brothers and both were compound heterozygous for a frame-
shift mutation in COL17A1 (human COL17A1 messenger
RNA (mRNA) sequence: GenBank accession number NM_
000494.3) in exon 30, c.2237delG;p.Gly746AlafsX53, and a
nonsense mutation in exon 51, c.3676C4T;p.Arg1226X
(Pasmooij et al., 2007b). These mutations were previously
referred to as c.2342delG and c.3781C4T, respectively. This
difference in numbering occurs because the initial nomen-
clature by Giudice et al. (1992) for the COL17A1 gene
included 105 additional nucleotides before the start codon
was reached, whereas the current nomenclature starts with
number 1 at the site of the start codon. The third (EB208-01)
and fourth (EB025-01) patients were homozygous for
c.2237delG, which is a common founder mutation in the
Netherlands (Scheffer et al., 1997).
Patient EB035-01
Patients EB035-01 and EB035-02 were born to non-
consanguineous parents. They have two brothers without
a blistering disease. Patient EB035-01, a 48-year-old man,
had blisters and large erosions since birth. Upon clinical
examination, we noted normal skin on the knees with
subpattelar calluses (Figure 1d). The patient indicated that
he walked on his knees indoors, because that skin area
developed no blisters. The dorsum of the hands showed
large hyperpigmented macules standing out against the pale,
hypopigmented, surrounding skin (Figure 2a and b).
Three biopsies R1, R2, and R3 were taken from hyper-
pigmented clinically healthy skin where no blisters occurred,
and one biopsy M1 was taken from the pale affected skin for
immunofluorescence microscopy (IF) and electron micro-
scopy (EM; Figure 1d). Staining for Col17 with NCC-Lu-226
in the affected skin biopsy (Figure 1b) was almost completely
absent along the basement membrane zone (BMZ) compared
with normal human control skin (4þ , Figure 1a). In contrast,
all biopsies taken from revertant skin showed reexpression of
Col17 (Figure 1a) with NCC-Lu-226 staining, corresponding
to about 75% of the intensity of normal human control skin
(Figure 1e, f, and g). Staining for 1D1 against the C-terminal
part of the ectodomain of Col17 was absent in the affected
skin biopsy, whereas reduced expression and loss of lateral
staining was observed in the revertant keratinocytes, corres-
ponding with the staining pattern of heterozygous carriers of
a recessive COL17A1 mutation (Pasmooij et al., 2007b). The
fraction of keratinocytes that reexpressed Col17 along the
BMZ varied from 8/10 in biopsy R1 to 9/10 in biopsies R2 and
R3. A tape strip test in which a small piece of tape was placed
on the skin and afterwards removed with tweezers (Gostynski
et al., 2009) showed no blister formation in the revertant skin
(Figure 1c), whereas peeling the epidermis in affected skin
resulted in epidermal–dermal separation (data not shown).
EM showed hemidesmosomes in revertant skin (R1 and
R3, data not shown) that were normal in shape and number.
In the biopsy taken from the left knee (R2), some basal cells
had normal hemidesmosomes, whereas other basal cells had
a low number of hypoplastic hemidesmosomes, which fits
with mosaicism at a cellular level. In line with the JEB-nH
phenotype, affected skin (M1) revealed a split through the
lamina lucida.
Patient EB035-02
Patient EB035-02, brother of patient EB035-01, who is 1.5
years younger, also presented with blisters after minor trauma
since birth. Clearly defined hyperpigmented areas were
present on the face, forehead, and dorsal sides of the hands
(Figure 2c). Similar to his brother, the patient did not know
whether the clinically unaffected patches were present
already at birth or had developed later in life.
Immunofluorescence staining for Col17 of the biopsy (M2)
from pale affected skin was absent with antibodies 1D1 and
1A8C, and almost absent with antibodies 233 and NCC-Lu-
226. Interestingly, the biopsy of the hyperpigmented patch of
the hand (R4) showed reexpression of Col17 over approxi-
mately 4/5 of the BMZ, whereas the other 1/5 resembled the
staining of the mutant skin biopsy (data not shown).
EM analysis of mutant skin revealed a lucidolytic split with
the basal membrane on the blister floor. No blister formation
was observed in the revertant skin (R4). Although the
hemidesmosomes were partly hypoplastic, the basal cells
had correct tonofilament projections to the hemidesmo-
somes.
Patient EB208-01
Patient EB208-01 was seen for the first time in our clinic
at the age of 46 years. He was the sixth child of non-
consanguineous parents. One brother and one sister had a
blistering disease and had died during the first year of their
lives. In addition, his mother had generalized blistering with
alopecia. No other family members were affected. No DNA
of any of the family members was available. Physical
examination showed generalized blistering, especially on
the lower arms and palms. Erosions were present on the left
upper leg, right ankle, and lower back. The patient had
atrophic alopecia of frontal scalp, eyebrows, eyelashes, and
beard, and had no secondary hair. Two hyperpigmented skin
patches on the dorsal side of the wrist did not show blisters
after rubbing (Figure 2d and e). The patient indicated that
he had noticed the first patch at around 10 years of age
(Figure 2d). The other non-blistering skin patch appeared
later in life (Figure 2e). Pictures taken in 2008 and 2011
revealed that the hyperpigmented patch did not change
in size.
IF antigen mapping for Col17 (1D1) of pale affected
skin (M3) was negative (Pasmooij et al., 2007b). Instead, the
biopsies of hyperpigmented revertant skin were positive for
1D1 in about 6/10 and 9/10 of the basal cells in biopsies R5
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M1
R1
R2
R3
Figure 1. Revertant biopsies of patient EB035-01. Absence of blister formation was noted on both the knees. (d) In addition, at least two round patches
of clinically healthy skin were present above the right knee. (b) A biopsy taken from affected skin showed lack of Col17 expression (M1) compared
with (a) normal human control skin. (e, f, g) Instead, all biopsies taken from unaffected skin (R1, R2, R3) showed reexpression of Col17. (c) A tape strip
test showed absence of blister formation in the revertant skin.
EB035-01
EB035-01 EB208-01
EB208-01
EB134-01
EB134-01
EB011-01
EB011-01 EB117-01
EB117-01
EB035-02
R4
R6
R5
R6
Figure 2. Revertant skin areas in generalized JEB-nH patients. (a, b) The pigmented patches of patient EB035-01 on both his hands resembled the
pigmented patches of his brother, i.e., (c) patient EB035-02. In a skin biopsy of patient EB035-02, revertant mosaicism was confirmed (R4). (d, e) The right
hand of patient EB208-01 showed two pigmented macular patches (R6 and R5, respectively). The positions of the biopsies are marked with black circles.
(f, g) The hands of patients EB011-01 and (h, i) EB117-001 also show similar pigmented areas on both the hands. (j, k) In the 8-year-old patient EB134-01,
the pigmented, non-blistering areas are indicated. Clearly visible are the blisters that occur in the surrounding area.
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and R6, respectively. The 1D1 staining of the revertant
keratinocytes was slightly reduced compared with normal
human control skin and the apical-lateral staining was
lacking.
EM showed hypoplastic hemidesmosomes with absence
of the subbasal dense plate in affected skin of the upper leg
(Supplementary Figure S1a online). The number of hemi-
desmosomes was reduced. The revertant skin biopsy (R6)
showed basal cells with hypoplastic hemidesmosomes and
basal cells with normal-sized hemidesmosomes (Supplemen-
tary Figure S1b online), fitting with cellular mosaicism. Most
of the hemidesmosomes had a subbasal dense plate. No EM
biopsy had been taken of the other revertant skin area.
Patient EB025-01
In 1994, patient EB025-01 last visited our polyclinic. Fifteen
years later, upon clinical examination, hyperpigmented
areas were noted on her back (Figure 3a), both the hands,
and lower and upper arms (Figures 3b and c). The patient
indicated that she did not develop blisters in these areas,
although she was unsure whether the clinically healthy areas
had expanded or how long they had been present. Although
she kindly provided us with pictures from her childhood,
the resolution was unfortunately too low to be helpful in
determining when these healthy patches had developed.
Interesting was the presence of some hairs in the unaffected
skin area on her arms (Figure 3d), whereas in the affected
patches hairs were absent. Staining with 233 showed absence
of Col17 in the affected skin biopsy (M4), whereas 3/4 of
the basal cells in the unaffected skin biopsy (R7) expressed
Col17 protein to an almost normal extent as in normal control
skin.
DNA analysis of revertant skin biopsies
To investigate the correction mechanism, laser dissection
microscopy was used to separate revertant keratinocytes
from mutant keratinocytes and from fibroblasts. Subsequent
DNA analysis of Col17-positive keratinocytes of biopsies
from distinct revertant patches showed different second-site
mutations (Supplementary Figure S2 online): c.2228-101_
2263þ70delinsCTCTTAACCATAGTG in biopsy R1, c.2259_
2263þ9del in biopsy R2, c.2227þ153_2336-318del in
biopsy R5, c.2238C4T in biopsy R6, and c.2263þ2T4C in
biopsies R3, R4, and R7. The c.2238C4T substitution
in combination with the germ-line c.2237delG mutation
changes the amino acid on position 746 from glycine (GGC)
to valine (GTC). None of the second-site mutations was
detected in DNA of mutant keratinocytes or in fibroblasts.
EB025-01 EB025-01
M4
R7
EB025-01EB025-01
EB084-01 EB029-01
Figure 3. Revertant skin in patients EB025-01, EB084-01, and EB029-01. Several clinically unaffected areas were present on the (a) back, and (b) lower
and (c) upper arms. After sun exposure, the clinically unaffected areas become easily noticeable because of their hyperpigmentation compared with
the surrounded skin that is hypopigmented. Note this difference in (a) the neck of the patient and (b) on the lower arm. (d) Occasionally, a hair was
present in the healthy skin area. (e) On the back of the 11-year-old boy, EB084-01, hyperpigmented areas were noticed that resembled the revertant skin
patches of patient EB025-01 for which in vivo reversion was confirmed on a protein and DNA level. (f) In patient EB029-01 with JEB-nH due to laminin-332
deficiency (Pasmooij et al., 2007a), the revertant skin areas were also pigmented compared with the surrounding affected skin.
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The indel mutation c.2228-101_2263þ 70delins15 in R2
deleted 206 base pairs (bp), including the last 101 bp of
intron 29, complete exon 30, and the first 70 bp of intron
30. Instead, 15 bp were inserted, of which 13 of the 15 bp
corresponded with a sequence ‘‘CTTAACCATAGTG’’ that
was present 3 bp after the 206-bp deletion. The large deletion
in R5, c.2227þ 153_2336-318del, consisted of 2,165 bp
and resulted in absence of exons 30 and 31. The indel
mutation c.2228-101_2263þ70delins15 and large deletion
c.2227þ 153_2336-318del are therefore predicted to result
in mRNA with skipping of exon 30, and skipping of exons 30
and 31, respectively.
The consequence of the somatic c.2259_2263þ9del,
c.2263þ 2T4C, and c.2238C4T mutations was checked
with the splice-site prediction program NetGene2 (http://
www.cbs.dtu.dk/services/NetGene2/). Both c.2259_2263þ
9del and c.2263þ 2T4C abolished the 50-donor splice site of
intron 30, hence skipping of exon 30 in the mRNA would be
expected. In contrast, the c.2238C4T transition was not
predicted to have a significant effect on either the 30-acceptor
splice site of intron 29 or on the 50-donor splice site of
intron 30.
RNA analysis of revertant skin biopsies
Four of the five second-site mutations, c.2228-101_2263þ
70delins15, c.2259_2263þ9del, c.2263þ 2T4C, and
c.2238C4T, affected splicing in a similar manner, by giving
rise to an exon 30–deleted in-frame mRNA transcript
(Figure 4). As expected, mRNA analysis of the revertant
keratinocytes with the large deletion c.2227þ 153_2336-
318del showed an in-frame transcript with a 108-bp deletion
of exons 30 and 31.
DISCUSSION
This study describes in four patients the in vivo reversion of
the c.2237delG COL17A1 mutation due to five different
second-site changes in seven skin biopsy specimens. The
correcting DNA changes involved a wide variety of different
mutations, i.e., a transition in the same codon (c.2238C4T),
a substitution in the 50-donor splice site of intron 30
(c.2263þ2T4C), a deletion in exon 30 and intron 30
(c.2259_2263þ 9del), an indel mutation (c.2228-101_2263þ
70delins15), and a 2,165-bp deletion (c.2227þ153_2336-
318del). Although many second-site mutations have been
discovered in patients with revertant mosaicism, an indel
mutation and a deletion of more than 2,000bp that revert the
phenotype to normal have not been previously observed.
Four of the five COL17A1 second-site mutations had the
same effect on the mRNA level, i.e., exon 30 was spliced out,
which resulted in a Col17 protein with a deletion of 12 amino
acids. This slightly smaller Col17 protein is functional, as
could be observed by the adhesive strip test that was
performed on revertant skin of the knee in patient EB035-
01. In addition, the mild localized phenotype of a previously
published JEB-nH patient EB098-01 (c.2251C4T;p.Gln751X,
c.3327delT) with outsplicing of the premature termination
codon–containing exon 30 illustrates the functionality of the
exon 30–deleted Col17 protein (Pasmooij et al., 2004b). The
second-site mutation c.2238C4T changed the amino acid at
position 746 to a valine. Although the program NetGene2
predicted no significant effect on mRNA splicing, exon 30
was skipped out. Subsequent analysis of exonic splicing
enhancers with ESEfinder (Cartegni et al., 2003) showed that
the combination of the c.2237delG and c.2238C4T muta-
tion compared with the wild-type sequence resulted in the
abolishment of two exonic splicing enhancers, and a minor
increase in score from a SF2/ASF site from 1.94 to 2.14. It
might be that the outsplicing of exon 30 is the result of this
increase in the SF2/ASF site. Another factor that could have
influenced splice-site selection is a possible effect of the
c.2238C4T on the RNA secondary structure, which in turn
may affect splicing (Shen et al., 1999; Buratti and Baralle,
2004). The mRNA data of the second-site mutation in R5
were aberrant from the other revertant biopsies, as deletion of
exons 30 and 31 was observed. This mRNA transcript
resulted in a functional Col17 protein with a deletion of 36
amino acids in the largest collagenous domain (Col15).
The clinically healthy skin patches all originated from a
distinct in vivo reversion event, because the correcting
COL17A1 mutations were all different within one patient.
Moreover, our results show that there is not a single preferred
mechanism for correction of the inherited c.2237delG
COL17A1 mutation. Similarly, in Wiskott–Aldrich Syndrome
multiple revertant clones were observed within one patient
correcting the same germ-line mutation. Davis et al. (2010)
described a patient with at least 38 different revertant
genotypes, comprising of deletions and base substitutions
that restored expression of WASp. In contrast, in patients with
‘‘ichthyosis with confetti’’ due to dominant KRT10 mutations,
the repair mechanism was in all normal skin spots mitotic
recombination of variable length (Choate et al., 2010). The
authors speculated that the mislocalization of the mutant
keratin 10 to the nucleolus might have elevated the mutation
rate for mitotic recombination, thereby resulting in thousands
of revertant clones.
Depending on the EB gene and the nature and location of
the inherited mutation, a certain germ-line mutation will have
more possibilities for correction than another inherited
mutation. It is known that skipping of exons 30 or 33 of
COL17A1 both lead to a milder phenotype (Ruzzi et al.,
2001; Pasmooij et al., 2004b). The c.2237delG COL17A1
mutation can thus be repaired by all mutations that result in
deletion of exon 30, whereas it is unknown whether deletion
of the 147-bp-containing exon 51 can result in a functional
Col17 protein. The c.3676C4T mutation in exon 51 was not
repaired in patients EB035-01 and EB035-02. Nonetheless,
correction of this mutation has occurred in other patients,
e.g., by a second-site mutation in the same codon
(c.3677G4C) changing the nonsense to a missense codon
(Pasmooij et al., 2005).
Natural gene therapy has now been confirmed on a DNA
level in the majority of the generalized JEB-nH patients with
COL17A1 mutations in the Netherlands, i.e., 6 out of 10
(60%), when the patients described in this article are
included. In fact, studying the photo-material of the other
four JEB-nH COL17A1 patients with generalized blistering
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(patients published in Jonkman and Pasmooij (2009)) indicates
in each patient one or more pigmented areas without blister
formation that are highly suspected for natural gene therapy
(Figures 2h, i, j, k, and 3e), as the areas closely resemble the
revertant skin patches of the patients for whom in vivo
reversion has been confirmed on a protein and DNA level.
No skin biopsies were taken from these four patients, of
whom two patients are deceased (EB011-01 and EB117-01)
and two patients are children (EB084-01 and EB134-01). EB
nevi can also be hyperpigmented, although EB nevi can
be distinguished from the revertant skin patches, as EB nevi
are often irregularly pigmented plaques, which may give rise
to small satellite nevi surrounding the primary nevus
(Lanschuetzer et al., 2010), whereas the revertant areas are
homogenously pigmented macules without satellites. As the
pigmented clinically healthy patches are very typical for
revertant mosaicism in these COL17A1 patients, we believe it
is fair to conclude that the majority, if not all patients with a
generalized nH-JEB phenotype have revertant mosaicism
(Table 1). In addition, in patients with JEB-nH due to LAMB3
COL17A1 DNA
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33
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Figure 4. COL17A1 messenger RNA (mRNA) analysis of revertant and mutant skin biopsies. (a) Schematic depiction of the COL17A1 gene with
introns and exons (boxes) with different complementary DNA (cDNA) transcripts of wild-type, Ex30_del, and Ex30þ 31_del given below. (b) Agarose
gel of cDNA amplified with primers F26 and R31. Lane EB098-01 represents cDNA from a patient who is known to have exon 30-skipping (Pasmooij
et al., 2004b). Wild-type cDNA resulted in a transcript of 218 bp, whereas the exon 30–deleted transcript was 182 bp in size. For the revertant biopsies
R1, R2, R3, R4, and R6, almost all cDNA originated from the corrected COL17A1 allele. For revertant biopsy R5 amplified with primers F26 and R31,
only cDNA was detected from the mutant COL17A1 allele carrying the c.2237delG mutation. (c) Agarose gel of cDNA amplified with primers F24/25
and R34. Wild-type cDNA resulted in a transcript of 444 bp. When cDNA of biopsy R5 was amplified with primers F24/25 and R34, a transcript of
336 bp was observed that lacked both exons 30 and 31 that originated from the corrected COL17A1 allele with the large deletion c.2227þ153_2336-318del.
This transcript lacking exons 30 and 31 could not be amplified with the primers F26 and R31 as used in agarose gel (b), as the sequence to which R31
attaches was missing in the shortened cDNA transcript. MWM, molecular weight marker; NC, negative control; PC, positive control.
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mutations, revertant areas are pigmented (for comparison see
Figure 3f), whereas such difference in (hyper)pigmentation is
not noticeable in patients with dystrophic EB and revertant
mosaicism (Almaani et al., 2010; Pasmooij et al., 2010; Van
den Akker et al., 2011). In contrast to the generalized JEB-nH
patients, in the COL17A1 patients with a localized JEB-nH
phenotype in the Netherlands, i.e., four patients in total,
revertant skin areas with hyperpigmentation were not obvious.
Although it cannot be excluded that in vivo reversion occurs in
these localized JEB-nH patients, possible revertant patches will
not be noticed as they will not clearly stand out, because the
skin from localized JEB-nH patients is not hypopigmented as in
generalized JEB-nH because of the presence of altered Col17.
The phenotype, genotype, and immunofluorescence antigen
mapping of three of these patients with localized disease were
extensively described earlier: EB086-01, EB098-01, and
EB168-01 (Pasmooij et al., 2004a, b, 2007b).
To observe the revertant skin patches, a reversion event
should have taken place in an epidermal stem cell, which
subsequently had a positive selection advantage in vivo,
followed by expansion leading to restoration of skin function.
COL17A1mutations that arise, which do not result in a stable
Col17 protein, will not provide any selective advantage, and
therefore will remain unnoticed. The revertant area in patient
EB035-01 did not noticeably change in size over a period
of 3 years, suggesting that the selection advantage would be
present during embryogenesis or early in childhood. For
example, patient EB208-01 indicated that he had noticed the
first revertant skin patch around 10 years of age. Up till now,
the patients described with Col17 deficiency and revertant
skin patches are all adults (Jonkman et al., 1997; Pasmooij
et al., 2005) from whom no pictures are available just after
birth. To learn more about the possible expansion of revertant
skin areas at a younger age, it would be interesting to
diagnose revertant mosaicism already in infancy in patients
with Col17 deficiency. The two children of 8 (EB134-01) and
11 (EB084-01) years of age will be closely followed up by us
(Table 1). Keratin 14, laminin-332, type VII collagen, and type
XVII collagen are all expressed in epidermal stem cells, and
consequently a selective advantage in revertant keratinocytes
could be expected when these proteins are expressed again,
or to a higher extent compared with their mutant counter-
parts. In an inducible mouse model for EB simplex, such
a selection advantage has been shown for epidermal stem
cells without the K14 mutation (Cao et al., 2001). It is
therefore anticipated that revertant mosaicism will also be
observed in patients with mutations in other EB genes that
code for proteins that are expressed by the basal keratino-
cytes, such as KRT5. No correcting somatic mutations were
found in the COL17A1 gene in fibroblast samples, which
seems only logical, as Col17 is not produced by fibroblasts;
thus, correction will not lead to a growth advantage, and
therefore such COL17A1 mutations will remain unnoticed.
As UV light can induce somatic mutations (Pfeifer et al.,
2005), this raises the question whether UV radiation has a
role in inducing the correcting mutations. Although revertant
patches were present in areas that are more frequently sun
exposed, such as the hands, many revertant patches were also
seen in areas that receive almost no sun exposure, arguing
against a major role of UV exposure. Although a role cannot
be excluded, indel mutations and large deletions are also not
typical UV-induced mutations. Nonetheless, one might profit
from the sun exposure in distinguishing the revertant skin
areas, as sun exposure increases the contrast in pigmentation
between revertant and mutant areas (Figure 3a and c). The
hyperpigmentation of Col17 revertant patches might be
explained by its pivotal role in pigment cell maintenance.
COL17A1-null mice display a pigment defect, as the hair is
white instead of black over the entire body (Nishie et al.,
2007). The same group recently showed that the expression
of Col17 in hair follicle stem cells is required for the mainte-
nance of melanocyte stem cells, which do not express Col17
(Tanimura et al., 2011). In the revertant patches, a Col17-
dependent niche is provided for the melanocyte stem cells,
whereas in the nonrevertant skin areas the melanocyte stem
cells will be depleted, which corresponds with the absence of
Col17 formation. The fact that the laminin-332 revertant
areas show (hyper)pigmentation suggests that there is also a
link between laminin-332 and the melanocyte stem cells.
In the future, revertant keratinocytes might be used for
obtaining a skin graft of ‘‘naturally corrected’’ cells to treat
affected skin. In a study by Gostynski et al. (2009), adhesive
stripping was proved to be effective to remove the epidermis.
Functional repair was not yet achieved because of the low
percentage of revertant cells in the graft. Consequently,
further research into optimal growth and selection conditions
for revertant keratinocytes is required before revertant cell
therapy can be brought into clinical practice. Another
exciting possibility is combining natural gene therapy with
induced pluripotent stem (iPS) cell technology. Recently, two
groups have successfully generated iPS cells from patients
with recessive dystrophic EB, and subsequently differentiated
these iPS cells, either spontaneously (Tolar et al., 2011b) or
induced (Itoh et al., 2011) into keratinocytes. Patient-specific
keratinocytes from revertant mosaic patches that have been
corrected spontaneously could be used as a source for
patient-specific iPS cells and provide an essentially unlimited
number of patient-specific cells for grafting. Alternatively, iPS
cells may be differentiated into both hematopoietic and
mesenchymal stem cells, which can home into blistered
areas of the skin following bone marrow transplantation
(Wagner et al., 2010; Tolar et al., 2011a): ‘‘from skin to blood
cell to repair skin’’. The fact that the majority, if not all,
generalized JEB-nH patients with COL17A1 mutations in the
Netherlands have revertant keratinocytes makes it even more
exciting to explore further therapeutic options with these
naturally corrected cells.
MATERIALS AND METHODS
Biopsy sites
After written, informed consent and local ethics committee approval,
and in accordance with the Declaration of Helsinki Principles,
punch-biopsy specimens were obtained.
Immunofluorescence. From patient EB035-01, four biopsies were
taken, from which three were from clinically unaffected skin of the
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right upper leg (R1, Figure 1e), left knee (R2, Figure 1f), and right
knee (R3, Figure 1g), and one from nonlesional affected skin of his
right upper leg (M1, Figure 1b). From patient EB035-02, one biopsy
was taken from clinically unaffected skin of the left hand (R4,
Figure 2c) and one from nonlesional affected skin of the upper arm
(M2). The biopsy specimens of patient EB208-01 were from
clinically unaffected skin of the wrist (R5 and R6, Figure 2d and e)
and from nonlesional affected skin of the right upper leg (M3). The
two biopsies from patient EB025-01 were from nonlesional affected
skin of the right lower arm (M4, Figure 3b) and nonlesional
unaffected skin of the right lower arm (R7, Figure 3b).
Electron microscopy. Four 2-mm punch-biopsy specimens were
obtained from patient EB035-01 from the same sites as the biopsies
that were taken for IF microscopy (R1, R2, R3, and M1). From patient
EB035-02, one biopsy was taken from nonlesional affected skin of
the back and clinically unaffected skin of the left hand (R4), and
from patient EB208-01 one biopsy was taken of nonlesional affected
skin of the upper leg (M3) and clinically unaffected skin of the
wrist (R6).
Immunofluorescence antigen mapping
mAbs for detection of Col17 were 1A8C, 1D1, NCC-Lu-226, and
233. 1A8C, 1D1, and 233 were gifts from Dr K. Owaribe, Nagoya,
Japan (Di Zenzo et al., 2004), whereas NCC-Lu-226 was a gift from
S. Hirohashi, Tokyo, Japan (Yamada et al., 1996). The fluorescence
signal was quantified using the image-processing program Image J
version 1.44 (http://rsbweb.nih.gov/ij/index.html). We assessed by
optical comparison which part of the BMZ of a skin section was
stained positively for type XVII collagen in the revertant skin
biopsies.
DNA and RNA isolation
DNA recovery of revertant and mutant keratinocytes was performed
as described previously (Pasmooij et al., 2005). For RNA isolation
and cDNA synthesis, the same methods were used as in Pasmooij
et al. (2010).
Identification of mutations in skin samples
For detection of mutations in laser dissection microscopy–isolated
DNA, we used nested PCR. All PCRs were repeated with templates
from at least three separate nucleic acid isolations obtained by
laser dissection microscopy. The cDNA samples from skin sections
were also subjected to nested PCR. Primer sequences are listed in
Supplementary Table S1 and S2 online.
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